Complement inhibitor eculizumab in thrombotic microangiopathy: Single-center case series.
Clin Case Rep
; 10(3): e05573, 2022 Mar.
Article
in En
| MEDLINE
| ID: mdl-35317070
ABSTRACT
Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Guideline
Aspects:
Patient_preference
Language:
En
Journal:
Clin Case Rep
Year:
2022
Document type:
Article